CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been given an average recommendation of “Moderate Buy” by the six research firms that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $5.02.

CTMX has been the subject of a number of research reports. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Wedbush reiterated an “outperform” rating and issued a $5.00 target price on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, StockNews.com lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 31st.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $0.46 on Friday. The stock has a 50-day simple moving average of $0.71 and a 200 day simple moving average of $0.94. CytomX Therapeutics has a twelve month low of $0.45 and a twelve month high of $5.85. The stock has a market capitalization of $36.49 million, a PE ratio of 2.68 and a beta of 1.33.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.45. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The company had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. As a group, equities research analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTMX. Miller Financial Services LLC acquired a new position in shares of CytomX Therapeutics in the 4th quarter worth approximately $26,000. Traphagen Investment Advisors LLC acquired a new position in CytomX Therapeutics during the fourth quarter worth $31,000. Algert Global LLC bought a new position in shares of CytomX Therapeutics during the fourth quarter valued at $35,000. Velan Capital Investment Management LP acquired a new stake in shares of CytomX Therapeutics in the 4th quarter valued at $36,000. Finally, Aspire Growth Partners LLC bought a new stake in shares of CytomX Therapeutics in the 4th quarter worth about $42,000. Institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.